losartan has been researched along with Atherogenesis in 38 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was a prospective, randomized, open, blinded endpoint study to assess the effects of angiotensin II type 1 receptor blocker, losartan, compared with calcium channel blocker, amlodipine, on left ventricular (LV) diastolic function and atherosclerosis of the carotid artery in Japanese patients with mild-to-moderate hypertension, LV hypertrophy, diastolic dysfunction and preserved systolic function." | 9.15 | The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. ( Akehi, N; Ebisuno, S; Fukui, S; Hori, M; Horiguchi, Y; Katsube, Y; Kobayashi, K; Kodama, M; Ohtsu, H; Ota, M; Ozaki, H; Sakai, A; Shimonagata, T; Takayasu, K; Yamamoto, K; Yamazaki, T, 2011) |
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 7.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| "Male rabbits (n = 48) were divided into control, hyperuricemia (HU), hypercholesterolemia + hyperuricemia (HC + HU) and high-purine with 30-mg/kg/d losartan (HU + losartan) groups." | 7.81 | Losartan alleviates hyperuricemia-induced atherosclerosis in a rabbit model. ( Ding, Y; Li, N; Miao, P; Zheng, H, 2015) |
| "To investigate whether the combination of fluvastatin and losartan synergistically relieve atherosclerosis and plaque inflammation induced by a high-cholesterol diet in rabbits." | 7.77 | Combination of fluvastatin and losartan relieves atherosclerosis and macrophage infiltration in atherosclerotic plaques in rabbits. ( Dong, B; Dong, QL; Jiang, H; Li, SY; Liu, CX; Liu, XX; Liu, ZZ; Wang, N; Xu, H; Yang, YP; Zhang, XH; Zhang, YH; Zhu, L, 2011) |
| "to investigate effects of Losartan on expression of connexin 40 and 43 (Cx40 and Cx43), in arteries at the early stage of atherosclerosis in a rabbit model." | 7.76 | Effects of Losartan on expression of connexins at the early stage of atherosclerosis in rabbits. ( Cai, W; Chen, JZ; Duan, JF; Ruan, LM, 2010) |
| " Angiotensin II (Ang II), one of the main vasoactive hormones of the renin-angiotensin system, has been associated with the development and progression of atherosclerosis." | 7.74 | Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension. ( Badimon, L; Costales, P; Huesca-Gómez, C; Llorente-Cortés, V; Sendra, J, 2008) |
| "This study was a prospective, randomized, open, blinded endpoint study to assess the effects of angiotensin II type 1 receptor blocker, losartan, compared with calcium channel blocker, amlodipine, on left ventricular (LV) diastolic function and atherosclerosis of the carotid artery in Japanese patients with mild-to-moderate hypertension, LV hypertrophy, diastolic dysfunction and preserved systolic function." | 5.15 | The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. ( Akehi, N; Ebisuno, S; Fukui, S; Hori, M; Horiguchi, Y; Katsube, Y; Kobayashi, K; Kodama, M; Ohtsu, H; Ota, M; Ozaki, H; Sakai, A; Shimonagata, T; Takayasu, K; Yamamoto, K; Yamazaki, T, 2011) |
| "The Telmisartan and Losartan Cardiac Evaluation Trial, a multicenter, prospective, randomized, open-labeled, blinded-endpoint trial, was designed to compare the effects of two angiotensin II receptor blockers (ARBs), telmisartan and losartan, on cardiovascular protection in Japanese patients with mild to moderate essential hypertension." | 5.15 | Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients. ( Hasegawa, H; Kobayashi, Y; Komuro, I; Mizuguchi, T; Namiki, T; Narumi, H; Ohtsuka, M; Takano, H, 2011) |
| "Hyperuricemia and angiotensin II (Ang II) may have a pathogenetic role in the development of hypertension and atherosclerosis as well as cardiovascular disease (CVD) and its prognosis." | 3.85 | Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44/42 MAPK and PDGFRβ. ( Çetin, A; Kırça, M; Oğuz, N; Uzuner, F; Yeşilkaya, A, 2017) |
| " However, direct comparison of Ang-(1-7) and angiotensin II type 1 receptor blocker (ARB) on atherogenesis is sparse." | 3.81 | Comparison of angiotensin-(1-7), losartan and their combination on atherosclerotic plaque formation in apolipoprotein E knockout mice. ( Dong, M; Guan, J; Meng, X; Niu, R; Sun, Y; Yang, J; Yang, X; Zhang, C; Zhang, Y, 2015) |
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 3.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| "Male rabbits (n = 48) were divided into control, hyperuricemia (HU), hypercholesterolemia + hyperuricemia (HC + HU) and high-purine with 30-mg/kg/d losartan (HU + losartan) groups." | 3.81 | Losartan alleviates hyperuricemia-induced atherosclerosis in a rabbit model. ( Ding, Y; Li, N; Miao, P; Zheng, H, 2015) |
| " Transcriptional screening of ACE-overexpressing monocytes revealed noticeably increased expression of Angiotensin II receptors and adhesion- as well as atherosclerosis-related ICAM-1 and VCAM1." | 3.80 | Uremic conditions drive human monocytes to pro-atherogenic differentiation via an angiotensin-dependent mechanism. ( Fiedler, R; Girndt, M; Seibert, E; Trojanowicz, B; Ulrich, C, 2014) |
| "To investigate whether the combination of fluvastatin and losartan synergistically relieve atherosclerosis and plaque inflammation induced by a high-cholesterol diet in rabbits." | 3.77 | Combination of fluvastatin and losartan relieves atherosclerosis and macrophage infiltration in atherosclerotic plaques in rabbits. ( Dong, B; Dong, QL; Jiang, H; Li, SY; Liu, CX; Liu, XX; Liu, ZZ; Wang, N; Xu, H; Yang, YP; Zhang, XH; Zhang, YH; Zhu, L, 2011) |
| "to investigate effects of Losartan on expression of connexin 40 and 43 (Cx40 and Cx43), in arteries at the early stage of atherosclerosis in a rabbit model." | 3.76 | Effects of Losartan on expression of connexins at the early stage of atherosclerosis in rabbits. ( Cai, W; Chen, JZ; Duan, JF; Ruan, LM, 2010) |
| "Immobilization stress induces vascular oxidative stress by activating the angiotensin II/AT(1) receptor signaling pathway, thereby provoking endothelial dysfunction which can contribute to the development of atherosclerosis and hypertension." | 3.76 | Immobilization stress induces endothelial dysfunction by oxidative stress via the activation of the angiotensin II/its type I receptor pathway. ( Chung, IM; Kim, CK; Kim, YM; Shin, MK; Suh, SH; Yoo, MH, 2010) |
| "Increasing evidence suggests that cathepsins and angiotensin II (AngII) participate in atherosclerosis, particularly in remodeling of the extracellular matrix of the inflamed arterial intima." | 3.74 | Angiotensin II increases expression and secretion of cathepsin F in cultured human monocyte-derived macrophages: an angiotensin II type 2 receptor-mediated effect. ( Kaakinen, R; Kovanen, PT; Lindstedt, KA; Oörni, K; Sneck, M, 2007) |
| "Angiotensin II (Ang-II) and mononuclear leukocytes are involved in atherosclerosis." | 3.74 | CXCR2 blockade impairs angiotensin II-induced CC chemokine synthesis and mononuclear leukocyte infiltration. ( Abu Nabah, YN; Company, C; Cortijo, J; Estellés, R; Jose, PJ; Lopez-Gines, C; Losada, M; Mateo, T; Morcillo, EJ; Piqueras, L; Sanz, MJ; Sarau, H, 2007) |
| " Angiotensin II (Ang II), one of the main vasoactive hormones of the renin-angiotensin system, has been associated with the development and progression of atherosclerosis." | 3.74 | Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension. ( Badimon, L; Costales, P; Huesca-Gómez, C; Llorente-Cortés, V; Sendra, J, 2008) |
| " A total of 50 patients with hypertension were divided into 3 groups: a control group receiving neither an ARB nor an ACE inhibitor (n = 14), a losartan group (n = 22) receiving 50 mg/day of losartan, and an ACE inhibitor group (n = 14) receiving either 5 mg/day of enalapril or 5 mg/day of imidapril." | 3.74 | A one-year study of the antiatherosclerotic effect of the angiotensin-II receptor blocker losartan in hypertensive patients. A comparison with angiotension-converting enzyme inhibitors. ( Aoyagi, T; Nagai, R; Sonoda, M; Takenaka, K; Uno, K, 2008) |
| "Our data do not support a role for the AT1 receptor in the progression of atherosclerosis in this model, since blockade with losartan did not alter plaque distribution." | 3.73 | Blood pressure is the major driving force for plaque formation in aortic-constricted ApoE-/- mice. ( Bergström, G; Gan, LM; Johansson, ME; Skøtt, O; Wickman, A, 2006) |
| "Treatment with losartan significantly attenuated aortic AS, inhibited ER stress and reduced aortic inflammation." | 1.46 | Renin-angiotensin system activation accelerates atherosclerosis in experimental renal failure by promoting endoplasmic reticulum stress-related inflammation. ( Gan, H; Tang, W; Yang, J; Yu, X; Zhang, X, 2017) |
| " The purpose of this study was to determine the relative effects of these three modes of pharmacological RAS inhibition in reducing atherosclerosis by determining the dose-response relationships." | 1.38 | Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis. ( Balakrishnan, A; Cassis, LA; Charnigo, R; Daugherty, A; Howatt, DA; Liau, G; Lu, H; Wu, C, 2012) |
| "Hydrochlorothiazide treatment was associated with hypokalemia, which was not present in losartan or indapamide treatment." | 1.36 | Comparative study of hydrochlorothiazide and indapamide on the anti-atherogenic potential of losartan in cholesterol fed rat. ( Islam, MZ; Rahman, MS, 2010) |
| "We investigated the effects of co-administration of an angiotensin-converting enzyme inhibitor (ACEI) and angiotensin type 1 receptor blocker (ARB) on nitric oxide (NO) bioavailability in genetically hyperlipidemic rabbits with our newly developed NO sensor." | 1.35 | Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist combination on nitric oxide bioavailability and atherosclerotic change in Watanabe heritable hyperlipidemic rabbits. ( Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Yoshida, K, 2008) |
| "Uremia was induced in apoE-/- mice by 5/6 nephrectomy (NX)." | 1.34 | Inhibition of the renin-angiotensin system abolishes the proatherogenic effect of uremia in apolipoprotein E-deficient mice. ( Binder, CJ; Bro, S; Nielsen, LB; Olgaard, K; Witztum, JL, 2007) |
| "Treatment with losartan did not affect serum lipid levels or systolic blood pressure but did reduce the aortic surface lesion area and mean intimal thickness." | 1.34 | Decreased infiltration of macrophages and inhibited activation of nuclear factor-kappa B in blood vessels: a possible mechanism for the anti-atherogenic effects of losartan. ( Li, GS; Li, JJ; Li, NX; Peng, J; Wang, J; Xu, HX, 2007) |
| "Amlodipine was found to induce TGF-beta synthesis from mononuclear cells with increasing concentrations, while it was found to inhibit TNF-alpha secretion with increasing concentrations." | 1.33 | TGF-beta and TNF-alpha producing effects of losartan and amlodipine on human mononuclear cell culture. ( Dikmen, T; Gul, S; Kaynar, K; Ovali, E; Ulusoy, S; Vanizor, B, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (44.74) | 29.6817 |
| 2010's | 18 (47.37) | 24.3611 |
| 2020's | 3 (7.89) | 2.80 |
| Authors | Studies |
|---|---|
| Wei, S | 1 |
| Sun, J | 1 |
| Li, Y | 1 |
| Xu, K | 1 |
| Wang, M | 1 |
| Zhang, Y | 3 |
| Sheng, J | 1 |
| Zu, Z | 1 |
| Zhu, H | 1 |
| Qi, J | 1 |
| Zheng, T | 1 |
| Tian, Y | 1 |
| Zhang, L | 1 |
| Elseweidy, MM | 1 |
| Elnagar, GM | 1 |
| M Elsawy, M | 1 |
| Ali, AA | 1 |
| Zein, N | 1 |
| Rauch, G | 1 |
| Beyersmann, J | 1 |
| Trojanowicz, B | 1 |
| Ulrich, C | 1 |
| Seibert, E | 1 |
| Fiedler, R | 1 |
| Girndt, M | 1 |
| Yang, J | 2 |
| Sun, Y | 1 |
| Dong, M | 1 |
| Yang, X | 1 |
| Meng, X | 1 |
| Niu, R | 1 |
| Guan, J | 1 |
| Zhang, C | 1 |
| Yamamoto, S | 1 |
| Zhong, J | 1 |
| Yancey, PG | 1 |
| Zuo, Y | 4 |
| Linton, MF | 4 |
| Fazio, S | 4 |
| Yang, H | 1 |
| Narita, I | 1 |
| Kon, V | 4 |
| Zheng, H | 1 |
| Li, N | 1 |
| Ding, Y | 1 |
| Miao, P | 1 |
| Kırça, M | 1 |
| Oğuz, N | 1 |
| Çetin, A | 1 |
| Uzuner, F | 1 |
| Yeşilkaya, A | 1 |
| Zhang, X | 2 |
| Yu, X | 1 |
| Tang, W | 1 |
| Gan, H | 1 |
| Yancey, P | 1 |
| Castro, I | 1 |
| Khan, WN | 1 |
| Khan, W | 1 |
| Motojima, M | 2 |
| Ichikawa, I | 3 |
| Fogo, AB | 3 |
| Apostolakis, S | 1 |
| Vlata, Z | 1 |
| Vogiatzi, K | 1 |
| Krambovitis, E | 1 |
| Spandidos, DA | 1 |
| Ruan, LM | 1 |
| Cai, W | 1 |
| Chen, JZ | 1 |
| Duan, JF | 1 |
| An, J | 1 |
| Nakajima, T | 1 |
| Kuba, K | 1 |
| Kimura, A | 1 |
| Chung, IM | 1 |
| Kim, YM | 1 |
| Yoo, MH | 1 |
| Shin, MK | 1 |
| Kim, CK | 1 |
| Suh, SH | 1 |
| Yamamoto, K | 1 |
| Ozaki, H | 1 |
| Takayasu, K | 1 |
| Akehi, N | 1 |
| Fukui, S | 1 |
| Sakai, A | 1 |
| Kodama, M | 1 |
| Shimonagata, T | 1 |
| Kobayashi, K | 2 |
| Ota, M | 1 |
| Horiguchi, Y | 1 |
| Ebisuno, S | 1 |
| Katsube, Y | 1 |
| Yamazaki, T | 1 |
| Ohtsu, H | 1 |
| Hori, M | 1 |
| Thatcher, SE | 1 |
| Howatt, DA | 2 |
| Lu, H | 2 |
| Gurley, SB | 1 |
| Daugherty, A | 2 |
| Cassis, LA | 2 |
| Islam, MZ | 1 |
| Rahman, MS | 1 |
| Hasegawa, H | 1 |
| Takano, H | 1 |
| Narumi, H | 1 |
| Ohtsuka, M | 1 |
| Mizuguchi, T | 1 |
| Namiki, T | 1 |
| Kobayashi, Y | 1 |
| Komuro, I | 1 |
| Yang, YP | 1 |
| Dong, QL | 1 |
| Zhang, XH | 1 |
| Zhang, YH | 1 |
| Zhu, L | 1 |
| Li, SY | 1 |
| Liu, ZZ | 1 |
| Xu, H | 1 |
| Wang, N | 1 |
| Jiang, H | 1 |
| Liu, CX | 1 |
| Liu, XX | 1 |
| Dong, B | 1 |
| Balakrishnan, A | 1 |
| Wu, C | 1 |
| Charnigo, R | 1 |
| Liau, G | 1 |
| Rius, C | 1 |
| Piqueras, L | 2 |
| González-Navarro, H | 1 |
| Albertos, F | 1 |
| Company, C | 2 |
| López-Ginés, C | 2 |
| Ludwig, A | 1 |
| Blanes, JI | 1 |
| Morcillo, EJ | 2 |
| Sanz, MJ | 2 |
| Kaynar, K | 1 |
| Ulusoy, S | 1 |
| Ovali, E | 1 |
| Vanizor, B | 1 |
| Dikmen, T | 1 |
| Gul, S | 1 |
| Suganuma, E | 2 |
| Ayabe, N | 2 |
| Ma, J | 1 |
| Babaev, VR | 2 |
| Johansson, ME | 1 |
| Wickman, A | 1 |
| Skøtt, O | 1 |
| Gan, LM | 1 |
| Bergström, G | 1 |
| Kaakinen, R | 1 |
| Lindstedt, KA | 1 |
| Sneck, M | 1 |
| Kovanen, PT | 1 |
| Oörni, K | 1 |
| Peng, N | 1 |
| Liu, JT | 1 |
| Gao, DF | 1 |
| Lin, R | 1 |
| Li, R | 1 |
| Naina, HV | 1 |
| Harris, S | 1 |
| Grothusen, C | 1 |
| Umbreen, S | 1 |
| Konrad, I | 1 |
| Stellos, K | 1 |
| Schulz, C | 1 |
| Schmidt, B | 1 |
| Kremmer, E | 1 |
| Teebken, O | 1 |
| Massberg, S | 1 |
| Luchtefeld, M | 1 |
| Schieffer, B | 1 |
| Gawaz, M | 1 |
| Bro, S | 1 |
| Binder, CJ | 1 |
| Witztum, JL | 1 |
| Olgaard, K | 1 |
| Nielsen, LB | 1 |
| Ruef, J | 1 |
| Browatzki, M | 1 |
| Pfeiffer, CA | 1 |
| Schmidt, J | 1 |
| Kranzhöfer, R | 1 |
| Abu Nabah, YN | 1 |
| Losada, M | 1 |
| Estellés, R | 1 |
| Mateo, T | 1 |
| Sarau, H | 1 |
| Cortijo, J | 1 |
| Jose, PJ | 1 |
| Xu, HX | 1 |
| Li, JJ | 1 |
| Li, GS | 1 |
| Wang, J | 1 |
| Li, NX | 1 |
| Peng, J | 1 |
| Sendra, J | 1 |
| Llorente-Cortés, V | 1 |
| Costales, P | 1 |
| Huesca-Gómez, C | 1 |
| Badimon, L | 1 |
| Hernandez-Trujillo, Y | 1 |
| Rodriguez-Esparragon, F | 1 |
| Macias-Reyes, A | 1 |
| Caballero-Hidalgo, A | 1 |
| Rodriguez-Perez, JC | 1 |
| Sonoda, M | 1 |
| Aoyagi, T | 1 |
| Takenaka, K | 1 |
| Uno, K | 1 |
| Nagai, R | 1 |
| Imanishi, T | 1 |
| Kuroi, A | 1 |
| Ikejima, H | 1 |
| Muragaki, Y | 1 |
| Mochizuki, S | 1 |
| Goto, M | 1 |
| Yoshida, K | 1 |
| Akasaka, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Monocytes Adhesion and Vascular Lesions in Vascular Access Success or Failure in Uremic Patients[NCT03231410] | 30 participants (Anticipated) | Observational | 2017-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for losartan and Atherogenesis
| Article | Year |
|---|---|
The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin II Type 2 Receptor Blockers; Antihyperte | 2011 |
Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Benzimidazoles; Benzoates; Ca | 2011 |
36 other studies available for losartan and Atherogenesis
| Article | Year |
|---|---|
Losartan Attenuates Atherosclerosis in Uremic Mice by Regulating Treg/Th17 Balance via Mediating PTEN/PI3K/Akt Pathway.
Topics: Animals; Atherosclerosis; Disease Models, Animal; Interleukin-10; Interleukin-17; Interleukin-6; Los | 2022 |
Targeted therapy of atherosclerosis by zeolitic imidazolate framework-8 nanoparticles loaded with losartan potassium
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents | 2022 |
Losartan and azelastine either alone or in combination as modulators for endothelial dysfunction and platelets activation in diabetic hyperlipidemic rats.
Topics: Alloxan; Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Blood Platelets; Diabete | 2020 |
Planning and evaluating clinical trials with composite time-to-first-event endpoints in a competing risk framework.
Topics: Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Clinical Trials as Topic; Computer Simulat | 2013 |
Uremic conditions drive human monocytes to pro-atherogenic differentiation via an angiotensin-dependent mechanism.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2014 |
Comparison of angiotensin-(1-7), losartan and their combination on atherosclerotic plaque formation in apolipoprotein E knockout mice.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Abdominal; Aortic Diseases; | 2015 |
Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.
Topics: Angiotensin Receptor Antagonists; Animals; Aortic Diseases; Apolipoproteins E; Apoptosis; Atheroscle | 2015 |
Losartan alleviates hyperuricemia-induced atherosclerosis in a rabbit model.
Topics: Animals; Antihypertensive Agents; Aorta; Atherosclerosis; Blotting, Western; Disease Models, Animal; | 2015 |
Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44/42 MAPK and PDGFRβ.
Topics: Angiotensin II; Animals; Atherosclerosis; Cardiovascular Diseases; Cell Proliferation; Gene Expressi | 2017 |
Renin-angiotensin system activation accelerates atherosclerosis in experimental renal failure by promoting endoplasmic reticulum stress-related inflammation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Biomarkers; Ce | 2017 |
Renal dysfunction potentiates foam cell formation by repressing ABCA1.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; ATP Binding Ca | 2009 |
Angiotensin II up-regulates CX3CR1 expression in THP-1 monocytes: impact on vascular inflammation and atherogenesis.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Cell Adhesi | 2010 |
Effects of Losartan on expression of connexins at the early stage of atherosclerosis in rabbits.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arteries; Atherosclerosis; Blotting, Western; Con | 2010 |
Losartan inhibits LPS-induced inflammatory signaling through a PPARgamma-dependent mechanism in human THP-1 macrophages.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Atherosclerosis; Cell Line | 2010 |
Immobilization stress induces endothelial dysfunction by oxidative stress via the activation of the angiotensin II/its type I receptor pathway.
Topics: Acetylcholine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Ag | 2010 |
Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor-/- mice.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2011 |
Comparative study of hydrochlorothiazide and indapamide on the anti-atherogenic potential of losartan in cholesterol fed rat.
Topics: Animals; Antihypertensive Agents; Atherosclerosis; Body Weight; Cholesterol, Dietary; Diuretics; Hyd | 2010 |
Combination of fluvastatin and losartan relieves atherosclerosis and macrophage infiltration in atherosclerotic plaques in rabbits.
Topics: Animals; Atherosclerosis; Chemokine CCL2; Cholesterol; Drug Synergism; Fatty Acids, Monounsaturated; | 2011 |
Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis.
Topics: Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhib | 2012 |
Arterial and venous endothelia display differential functional fractalkine (CX3CL1) expression by angiotensin-II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Arteries; Arter | 2013 |
TGF-beta and TNF-alpha producing effects of losartan and amlodipine on human mononuclear cell culture.
Topics: Amlodipine; Antihypertensive Agents; Atherosclerosis; Cells, Cultured; Humans; Leukocytes, Mononucle | 2005 |
Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atherosclerosis; Choleste | 2006 |
Blood pressure is the major driving force for plaque formation in aortic-constricted ApoE-/- mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Valve Stenosis; Atherosclerosis; Blood Pres | 2006 |
Angiotensin II increases expression and secretion of cathepsin F in cultured human monocyte-derived macrophages: an angiotensin II type 2 receptor-mediated effect.
Topics: Angiotensin II; Atherosclerosis; Cathepsin F; Cathepsins; Cell Survival; Humans; Imidazoles; Losarta | 2007 |
Angiotensin II-induced C-reactive protein generation: inflammatory role of vascular smooth muscle cells in atherosclerosis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; C-Reactive Protei | 2007 |
ACE inhibitors and aortic rupture.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2006 |
EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of AT1-receptor antagonism: potential impact on atherothrombosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Flow Cytometry; Humans; Losartan; Microsco | 2007 |
Inhibition of the renin-angiotensin system abolishes the proatherogenic effect of uremia in apolipoprotein E-deficient mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antibodi | 2007 |
Angiotensin II promotes the inflammatory response to CD40 ligation via TRAF-2.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; CD40 Antigens; CD40 Ligand | 2007 |
Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aortic Di | 2007 |
CXCR2 blockade impairs angiotensin II-induced CC chemokine synthesis and mononuclear leukocyte infiltration.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Cell Adhesion; Ce | 2007 |
Decreased infiltration of macrophages and inhibited activation of nuclear factor-kappa B in blood vessels: a possible mechanism for the anti-atherogenic effects of losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Cell Migration Inhibition; Diseas | 2007 |
Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; An | 2008 |
Rosiglitazone but not losartan prevents Nrf-2 dependent CD36 gene expression up-regulation in an in vivo atherosclerosis model.
Topics: Animals; Aryldialkylphosphatase; Atherosclerosis; Carboxylic Ester Hydrolases; CD36 Antigens; Choles | 2008 |
A one-year study of the antiatherosclerotic effect of the angiotensin-II receptor blocker losartan in hypertensive patients. A comparison with angiotension-converting enzyme inhibitors.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2008 |
Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist combination on nitric oxide bioavailability and atherosclerotic change in Watanabe heritable hyperlipidemic rabbits.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; An | 2008 |